Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

Previous clinical studies suggested that - when combined with changes to their diet, exercise and behavioural support - ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

More American teenagers now use the weight-loss drug Wegovy, as doctors and families grow more comfortable with the treatment ...

Drugmaker Novo Nordisk (NVO), on Thursday, announced a $199-per-month offer for self-paying patients new to its weight loss ...

Almost exactly a year after launching its Obesity Association, the American Diabetes Association (ADA) has recruited Novo ...

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy ...

As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient ...

Regeneron's trevogrumab trial has proved, overall, successful - potentially providing a solution to a reported Wegovy side ...

Regeneron highlighted that about 35% of weight loss from semaglutide alone was due to lean mass loss, which combo therapies ...

Novo Nordisk A/S is selling its blockbuster weight-loss drug Wegovy to new patients at $199 for the first month as easy access to cheaper copycats comes to an end. The one-time offer — available ...

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month, its CEO said on Wednesday after the ...